CN-Bio Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
56
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$34.8M
- Investors
-
10
CN-Bio General Information
Description
Developer of a microphysiological system intended for advancing biomedical research and drug development. The company's system replicates the microenvironment of human organs and tissue and incorporates fluidic channels to simulate the flow of nutrients, oxygen, and other biochemical factors, mimicking the physiological conditions of blood circulation in vivo, enabling pharma and biotech companies to improve their effectiveness and efficiency of preclinical drug testing.
Contact Information
Website
www.cn-bio.comCorporate Office
- 332 Cambridge Science Park
- Milton Road
- Cambridge CB4 0WN
- England, United Kingdom
Corporate Office
- 332 Cambridge Science Park
- Milton Road
- Cambridge CB4 0WN
- England, United Kingdom
CN-Bio Timeline
CN-Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC (Series B) | 23-Apr-2024 | $34.8M | Completed | Generating Revenue | ||
| 10. Later Stage VC | 01-Sep-2021 | Completed | Generating Revenue | |||
| 9. Grant | 01-Jan-2021 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 02-Mar-2020 | Completed | Generating Revenue | |||
| 7. Grant | 11-Oct-2017 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 21-Sep-2016 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 22-Feb-2016 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 01-Jun-2014 | Completed | Startup | |||
| 3. Later Stage VC | 10-Jul-2013 | $1.99M | $1.99M | Completed | Startup | |
| 2. Grant | $26.3M | Completed | Startup |
CN-Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 24,875 | $0.012543 | $37.63 | $37.63 | 1x | $37.63 | 3.87% | |
| Ordinary | 92,421 | $0.012543 | $41.39 | $41.39 | 1x | $41.39 | 14.37% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
CN-Bio Comparisons
Industry
Financing
Details
CN-Bio Competitors (20)
One of CN-Bio’s 20 competitors is MIMETAS, a Venture Capital-Backed company based in Oegstgeest, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MIMETAS | Venture Capital-Backed | Oegstgeest, Netherlands | ||||
| Hesperos | Venture Capital-Backed | Orlando, FL | ||||
| Ncardia | Venture Capital-Backed | Leiden, Netherlands | ||||
| InSphero | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Nagi Bioscience | Venture Capital-Backed | Saint-Sulpice, Switzerland |
CN-Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CN-Bio Patents
CN-Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202404504-D0 | Pumping means for a microfluidic device | Pending | 28-Mar-2024 | ||
| GB-202404519-D0 | Removable module for the culture of cells in a perfused device | Pending | 28-Mar-2024 | ||
| GB-202404405-D0 | Pneumatically dampened microfluidic device | Pending | 27-Mar-2024 | ||
| US-20250123273-A1 | System to calculate human oral bioavailability | Pending | 13-Oct-2023 | ||
| GB-202307455-D0 | Improvements in cell culture | Pending | 18-May-2023 | C12M23/38 |
CN-Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CN-Bio Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bayland Capital | Corporate Venture Capital | Minority | ||
| CITIC Capital | Asset Manager | Minority | ||
| GrayBella Capital | Venture Capital | Minority | ||
| CITIC Securities | Investment Bank | Minority | ||
| Pluto Finance (UK) | PE-Backed Company | Minority |
CN-Bio FAQs
-
When was CN-Bio founded?
CN-Bio was founded in 2008.
-
Where is CN-Bio headquartered?
CN-Bio is headquartered in Cambridge, United Kingdom.
-
What is the size of CN-Bio?
CN-Bio has 56 total employees.
-
What industry is CN-Bio in?
CN-Bio’s primary industry is Discovery Tools (Healthcare).
-
Is CN-Bio a private or public company?
CN-Bio is a Private company.
-
What is the current valuation of CN-Bio?
The current valuation of CN-Bio is .
-
What is CN-Bio’s current revenue?
The current revenue for CN-Bio is .
-
How much funding has CN-Bio raised over time?
CN-Bio has raised $54.8M.
-
Who are CN-Bio’s investors?
Bayland Capital, CITIC Capital, GrayBella Capital, CITIC Securities, and Pluto Finance (UK) are 5 of 10 investors who have invested in CN-Bio.
-
Who are CN-Bio’s competitors?
MIMETAS, Hesperos, Ncardia, InSphero, and Nagi Bioscience are some of the 20 competitors of CN-Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
